Etentamig

N/A

Report date: 2026/03/26 20:00:17

Base Information

Drug NameEtentamig
Drug Alias NameTNB-383BABBV-383
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionB-cell maturation protein inhibitorsT cell surface glycoprotein CD3 inhibitors
TargetsT cell surface glycoprotein CD3B-cell maturation protein
Therapy Area/IndicationsWaldenstrom MacroglobulinemiaMultiple MyelomaImmunoglobulin Light-chain Amyloidosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumCanada +[26] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 3 Clinical
Originator CompaniesTeneoOne Inc
China Registration ClassN/A

Develop Information

Active CompaniesAbbvie IncAbbvie Deutschland Gmbh & Co KgMayo Clinic +[4] 
Inactive CompaniesN/A
Active IndicationsWaldenstrom MacroglobulinemiaMultiple MyelomaImmunoglobulin Light-chain Amyloidosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A